N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including cystic fibrosis and asthma. The primary endpoint of the study is patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201, including effects on the airway.
Charles Scoggin, chairman of N30 Pharma, said: “We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to asthmatic, as well as healthy human subjects, is an important step.”